Physician profile
David Zarate
NPI 1194372417
$7,670.25
in general payments reported to CMS, 2019-2025
9 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $244 · 2021: $2,902 · 2022: $962 · 2023: $139 · 2024: $166 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,660 · Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,659.75 |
| Food and Beverage | $762.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,504.12 | 2019-2025 | Argos, Tryptyr, Dailies Total1 |
| Coopervision INC. | $2,816.91 | 2020-2025 | |
| Biotissue Holdings INC. | $161.70 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.66 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $29.70 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $17.11 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $13.96 | 2019 | |
| Lombart Brothers, INC. | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zarate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.